Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LIBerate-VI: lerodalcibep versus inclisiran for additional LDL-C reduction in high-risk cardiovascular patients
2021-002871-20Phase 3Completed
- Sponsor
- LIB Therapeutics, LLC
- Start
- Dec 2021
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in atherosclerotic disease and hypercholesterolemia comparing Lerodalcibep monthly with Inclisiran (2 arms). Primary endpoint: Percent change from baseline in LDL-C at Day 270. Started Dec 2021; status: completed.
02
Drugs
lerodalcibepinclisiran
03
Conditions
atherosclerotic diseasehypercholesterolemia
Beyond the preview
Go deeper on 2021-002871-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-002871-20.